Collaborations

Alliance with Baxter to discover anti-MIF antibody

Published in Drug Week, February 13th, 2004

Dyax Corp. (DYAX) announced a research collaboration with Baxter Healthcare Corporation (BAX) to utilize Dyax's proprietary phage display technology to discover antibodies that block macrophage migration inhibitory factor (MIF), a clinical target to which Baxter has an exclusive license from Cytokine PharmaSciences, Inc.

Under the terms of the agreement, Dyax and Baxter will conduct a research program to identify and characterize antibodies that bind specifically to MIF and neutralize its activity. MIF is a cytokine involved in immune, infectious, and malignant disorders. Neutralizing MIF activity may be useful in the treatment of a wide spectrum of diseases, including...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry